Hims & Hers

What it is

Hims & Hers began offering compounded injectable semaglutide in May 2024 and bought 503B compounder MedisourceRx in September 2024.

In March 2026 it agreed with Novo Nordisk to offer Wegovy and Ozempic at Novo's self-pay prices and to stop advertising compounded GLP-1s.

Its June 2026 10-Q says it shifted its US weight-loss offering to branded GLP-1s while offering compounded GLP-1s on a limited scale.

Hims & Hers describes its platform as giving access to treatments for sexual health, hair loss, hormone health, weight loss, dermatology and mental health, plus lab testing.

Its 10-K says prescriptions are filled through the company's wholly-owned pharmacies.

On September 10, 2025 Hims announced a testosterone category starting with compounded enclomiphene, with branded oral testosterone (Kyzatrex) and injectable testosterone planned for 2026.

The company says its compounded testosterone-support product (Testosterone Rx) is not FDA-approved or evaluated.

Prescribes: Brand-name Wegovy and Ozempic (since March 2026) plus compounded GLP-1s on a limited scale Generic and brand prescription drugs plus compounded products; for low testosterone, compounded enclomiphene (not FDA-approved), with branded Kyzatrex oral testosterone announced for 2026.

By the numbers

• Trustpilot 2.9/5 from 9,576 reviews (29% of ratings are 1-star; 38% are 5-star; checked 2026-10-15).9
• BBB: Not Rated; BBB Accredited since Feb 2018; 4,515 complaints in the last 3 years (checked 2026-10-15).10
• Trustpilot: 2.9/5 from 9,574 reviews (38% five-star, 29% one-star), checked 2026-10-15.7
• BBB: Not Rated rating, accredited, 4515 complaints filed in the last 3 years.10

Pros and cons

What users say

Common themes in public posts on Reddit, Trustpilot, the Better Business Bureau and app stores, summarised and linked. Individual experiences vary.

• Reviewers like the simple signup and easy video visits.7
• Weight-loss reviewers complain about membership fees on top of drug costs, late cold-chain deliveries and refund confusion.7
• Hims & Hers' February 2026 plan to sell a low-priced compounded semaglutide pill, its withdrawal days later, and Novo Nordisk's patent suit were among the busiest GLP-1 threads of the year; many commenters criticised the move, while others worried the fallout would restrict compounded access for everyone.151617
• After the semaglutide shortage ended in early 2025, members reported Hers messages saying standard-dose compounded semaglutide would stop while 'personalized' doses could continue; some said their dose was changed slightly to qualify.1819
• In a 2025 thread asking whether Hers works, several members reported losing 30 to 50 pounds on its compounded semaglutide, while the original poster described slow loss and a suggestion to switch to a brand-name drug that would cost about three times more.20
• By mid-2026 members describe Hims & Hers as moving to brand-name GLP-1s through its drugmaker partnerships rather than compounded versions.21
• Trustpilot reviewers like the simple process and some report good results, but complaints cite refills shipped or charged before reminders, shipping gaps and melted cold packs, and the membership-plus-medication cost.9
• Many reviewers find signup and ordering quick and the clinician guidance clear.7
• Frequent complaints about membership fees, rising prices and charges reviewers did not expect, including after cancelling.7
• Reports of hard-to-reach customer service and shipping or refill delays.7
• In r/erectiledysfunction, several users describe Hims as quick and easy to get approved and say the medication worked, while noting it costs more than a regular prescription.2728
• Commenters often point to cheaper routes for the same generic pills: a GoodRx telehealth visit, Amazon Pharmacy, Cost Plus Drugs or their own doctor.272930
• Some long-term users of its daily tadalafil report steady results and like not having to plan ahead.27
• Trustpilot reviewers: membership fee plus prescription cost adds up and prices rise over time.7
• Trustpilot reviewers: phone support hard to reach; account and subscription issues hard to resolve.7
• Trustpilot reviewers: delayed or missed deliveries.7
• Trustpilot reviewers: pricing and membership terms felt unclear at sign-up.7

Records we found

Official and court records we found in public sources as of October 15, 2026. This is not a live or complete record; check fda.gov, ftc.gov and court sites for the latest.

1. Jul 2026
   FTC

   The FTC, joined by Utah and Los Angeles County, sued Hims & Hers in N.D. California alleging violations of the FTC Act and ROSCA related to billing, cancellation and health-data sharing; the allegations are unproven.6

2. Jul 2026
   FTC

   The FTC, with Utah and California, filed a complaint in N.D. California alleging deceptive privacy practices, charging and enrolling consumers in subscriptions soon after intake, and making cancellation difficult; the company disputes the claims and the court has not ruled.22

3. Mar 2026
   Court

   Novo Nordisk voluntarily dismissed the patent suit without prejudice after an agreement under which Hims & Hers would stop advertising compounded GLP-1s.5

4. Feb 2026
   FDA

   FDA announced intent to restrict GLP-1 APIs used in non-approved compounded drugs, naming Hims & Hers as an example of mass marketing of compounded GLP-1s.8

5. Feb 2026
   Court

   Novo Nordisk filed a patent infringement suit against Hims & Hers in the U.S. District Court for the District of Delaware over compounded semaglutide.4

6. Sep 2025
   FDA

   FDA sent a warning letter to Hims & Hers (hims.com) citing claims including 'Same active ingredient as Ozempic and Wegovy' and 'Clinically proven ingredients' as false or misleading for compounded semaglutide.1

7. Sep 2025
   FDA

   FDA sent a parallel warning letter regarding compounded semaglutide claims on forhers.com.2

8. Sep 2025
   FDA

   FDA issued a warning letter (dated Sept 9, 2025) stating that claims on hims.com about compounded semaglutide implied the products are the same as FDA-approved drugs when they are not.1